Literature DB >> 12456591

Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis.

Takafumi Uchida1, Hajime Suto, Chisei Ra, Hideoki Ogawa, Tetsuji Kobata, Ko Okumura.   

Abstract

Lesional skin of patients with atopic dermatitis (AD) is histologically characterized by hypertrophy of the skin, and the infiltration of a large number of eosinophils and T cells into the dermis. Recent studies have indicated that Th2 cells play a crucial role in the pathogenesis of AD skin. Chemokines and their receptors are implicated in the development of symptoms of various skin diseases such as AD and psoriasis vulgaris (psoriasis). We have examined the in situ expression of a typical Th2-type chemokine, thymus- and activation-regulated chemokine (TARC), and its receptor (CCR4) using immunohistochemical techniques. TARC was found to be highly expressed in the basal epidermis of the lesional skin of AD patients and only slightly in the non-lesional skin. On the other hand, no positive cells were seen in the lesional skin of psoriasis. Consistently, CCR4+ cells were present predominantly in the lesional skin of AD patients, but not in the non-lesional skin. In contrast, in the lesional skin of psoriasis patients, cells positive for CCR5, which is expressed on Th1 cells, were abundantly present. Interestingly, psoralen plus ultraviolet A therapy reduced the number of CCR4+ cells in the AD skin lesions. These results suggest that Th2-type cytokines such as TARC are involved in the pathogenesis of skin lesions in AD patients through the preferential recruitment of Th2 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456591     DOI: 10.1093/intimm/dxf109

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

Review 1.  Chemokines: control of primary and memory T-cell traffic.

Authors:  Patrick Schaerli; Bernhard Moser
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  CCR6 as a possible therapeutic target in psoriasis.

Authors:  Michael N Hedrick; Anke S Lonsdorf; Sam T Hwang; Joshua M Farber
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

3.  Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model.

Authors:  Motonobu Nakamura; Jun-ichiro Jo; Yasuhiko Tabata; Osamu Ishikawa
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

4.  Phenotype of atopic dermatitis subjects with a history of eczema herpeticum.

Authors:  Lisa A Beck; Mark Boguniewicz; Tissa Hata; Lynda C Schneider; Jon Hanifin; Rich Gallo; Amy S Paller; Susi Lieff; Jamie Reese; Daniel Zaccaro; Henry Milgrom; Kathleen C Barnes; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2009-06-27       Impact factor: 10.793

Review 5.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

6.  Immunomodulatory effect of water soluble extract separated from mycelium of Phellinus linteus on experimental atopic dermatitis.

Authors:  Ji Sun Hwang; Ho-Keun Kwon; Jung-Eun Kim; Jeonghae Rho; Sin-Hyeog Im
Journal:  BMC Complement Altern Med       Date:  2012-09-18       Impact factor: 3.659

7.  The human cutaneous chemokine system.

Authors:  Michelle L McCully; Bernhard Moser
Journal:  Front Immunol       Date:  2011-08-09       Impact factor: 7.561

8.  Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor.

Authors:  Marjan de Groot; Marcel B M Teunissen; Jean P Ortonne; Julien R Lambert; Jean M Naeyaert; Daisy I Picavet; M Gladys Arreaza; Jason S Simon; Maarten Kraan; Jan D Bos; Menno A de Rie
Journal:  Arch Dermatol Res       Date:  2007-07-24       Impact factor: 3.017

9.  Synergic Anti-Pruritus Mechanisms of Action for the Radix Sophorae Flavescentis and Fructus Cnidii Herbal Pair.

Authors:  Jiali Zhong; Zhihong Liu; Xinxin Zhou; Jun Xu
Journal:  Molecules       Date:  2017-09-04       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.